Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications

Kidney International

Volumn 91, Issue 3, 2017, Pages 529-531

  Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; TELMISARTAN;

BLOOD PRESSURE MEASUREMENT; CAPILLARY PRESSURE; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NOTE; PREDICTIVE VALUE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; KIDNEY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; RENIN-ANGIOTENSIN SYSTEM;

EID: 85013025389     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.11.019     Document Type: Note

References (9)

1. 1 Clase, C.M., Barzilay, J., Gao, P., et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 91 (2017), 683–690.
2. 2 Yusuf, S., Teo, K.K., Pogue, J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
3. 3 Yusuf, S., Teo, K., Anderson, C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008), 1174–1183.
4. 4 Yusuf, S., Sleight, P., Pogue, J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000), 145–153.
5. 5 Pfeffer, M.A., Braunwald, E., Moye, L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992), 669–677.
6. 6 Brenner, B.M., Cooper, M.E., de, Z.D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
7. 7 Holtkamp, F.A., de, Z.D., Thomas, M.C., et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80 (2011), 282–287.
8. 8 Weir, M.R., Bakris, G.L., Weber, M.A., et al. Renal outcomes in hypertensive black patients at high cardiovascular risk. Kidney Int 81 (2012), 568–576.
9. 9 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.